Vizex Investments Ltd
financial consultations

Last news

Transenterix announces 1st US sale

Nov 13, 2017 4
November 13th. Transenterix Inc…

We no longer recommend Array Biopharma Inc

Nov 11, 2017 5
November 11th 2017. We are withdrawing…

Transenterix announces 1st US sale

November 13th.  Transenterix Inc announced that the company has sold a Senhance robot to Florida Hospital.  Florida Hospital is a member of Adventist Health System, which operates 45 hospitals in 9 states, making it one of the largest not-for-profit healthcare systems in the United States, caring for more than 5 million patients annually. 

We no longer recommend Array Biopharma Inc

November 11th 2017.  We are withdrawing our recommendation on Array Biopharma.  Please see or ARTICLES section for financial results of the recommendation.  Congratulations to all the long term investors who have been following the stock over 1 year period.  We are looking forward to publishing a new long term free recommendation in the coming days.  Keep checking our site.

Transenterix announces Q3 2017 results

November 9th.  Transenterix announced financial results and business update for Q3 2017

Key highlights

-The Senhahce robot has been approved by FDA for commercial sales in the U.S

-1 robot sold in Taiwan in Q3 2017

-Commercial infrastructure built in the U.S. - 17 sales representatives in place.

-1 sales pending (pre order issued) in EU - to be booked in Q4

-At least 1 sale expected in the U.S. in Q4

-$100 M cash in bank - enough to keep the company running well beyond 2018

FDA approves Transenterix Senhance robot for commercial sales in the U.S.

October 14th. TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the Company has received FDA 510(k) clearance for the Senhance™ Surgical Robotic System. With this clearance, the Senhance becomes the first new market entrant into the field of abdominal surgical robotics since 2000. The approval opens the way for Transenterix to the biggest robotic surgery market - the U.S. And the company along with Intuitive Surgical became the second major player on the global market.

Вайзекс Инвестментс ООД © 2015 | Всички права запазени